A number of investment brokers have recently updated their price targets on shares of Cymabay Therapeutics Inc. (CBAY). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/30/2016 – Cymabay Therapeutics Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 6 price target on the stock.

07/21/2015 – Piper Jaffray began new coverage on Cymabay Therapeutics Inc. giving the company a “overweight” rating. They now have a USD 4 price target on the stock.

05/08/2015 – Cymabay Therapeutics Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 9 price target on the stock.

05/01/2015 – Cymabay Therapeutics Inc. had its “hold” rating reiterated by analysts at Zacks.

02/18/2015 – Cymabay Therapeutics Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 16 price target on the stock.

08/15/2014 – Cymabay Therapeutics Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 15 price target on the stock.

The share price of Cymabay Therapeutics Inc. (CBAY) was up +0.00% during the last day of trading, with a day high of 2.54. 99971 shares were traded during the last session.

The stock’s 50 day moving average is 1.91 and its 200 day moving average is 1.51. The stock’s market capitalization is 56.98M. Cymabay Therapeutics Inc. has a 52-week low of 0.82 and a 52-week high of 4.89.

View other investors thoughts on Cymabay Therapeutics Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.